DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Retatrutide is a triple-hormone agonist with the deepest weight loss of any GLP-1-class molecule. TRIUMPH-1 Phase 3 (May 2026) showed 28.3% average loss at 80 weeks, up to 30.3% in higher-BMI cohorts, surpassing every approved drug.
Retatrutide adds glucagon-receptor agonism to the GLP-1 + GIP dual mechanism of tirzepatide. The glucagon arm increases energy expenditure and drives hepatic fat mobilization, on top of the appetite suppression and insulinotropic effects of GLP-1/GIP. This three-pathway approach is why TRIUMPH-1 weight loss exceeded all prior agents.
Versus Zepbound (tirzepatide, ~21% at 72 weeks): retatrutide TRIUMPH-1 hit 28.3% at 80 weeks, roughly a 7-percentage-point edge, the largest gap any candidate has shown over the current leader. The glucagon component also shows promise for fatty-liver (MASH) outcomes. If the remaining TRIUMPH trials confirm, retatrutide becomes the new efficacy ceiling.
TRIUMPH-1 topline reported May 21, 2026 (28.3% at 80 weeks). NDA submission expected by end of 2026 if remaining TRIUMPH trials succeed; FDA approval likely 2027. Weight-management and T2D indications both in development.
Patients who plateaued on tirzepatide at maximum dose, and those with concurrent fatty-liver disease. Not available outside trials yet; do not delay current treatment waiting for it.
Retatrutide TRIUMPH-1 Phase 3 results (May 2026) ↗
Editorial summary of investigational drugs not yet FDA-approved. Trial data and timelines change. Not medical advice; do not delay current treatment waiting for pipeline agents.